Curigen Pharmaceuticals LLP

Curigen Pharmaceuticals LLP - pharma in Surat, Gujarat, India. Directors, charges & compliance details.
LLPIN AAM-7893 Incorporated 08 June 2018 ROC Ahmedabad HQ Surat, Gujarat, India
Active Limited Liability Partnership pharma
Revenue · FY 2025
₹5.36 Cr
▲ 515% YoY
Net profit · FY 2025
₹4.26 Lakh
Net margin 0.8%
EBITDA · FY 2025
₹9.7 Lakh
EBITDA margin 1.8%
Contribution obligation
₹25 Lakh
As per LLP agreement
Open charges
₹1 Cr
Secured borrowings
LLP age
8 yrs
Est. 2018
Designated partners
3
As per MCA filings
Active GSTINs
1
GST registered

About Curigen Pharmaceuticals LLP

Data last updated:

Curigen Pharmaceuticals LLP is a limited liability partnership (LLP) based in Surat, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 June 2018 and has been in existence for over 8 years.

The LLP is registered with the Registrar of Companies (ROC), Ahmedabad, under LLPIN AAM-7893. Its GSTIN is 24ADRFS5465M1Z9 (Gujarat).

The LLP has a total obligation of contribution of ₹25 Lakh. It is led by designated partners including Krishna Sanjaykumar Maniya and Sanjaykumar Popatbhai Maniya.

Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Surat, Gujarat.

As per the financials filed for FY 2025, the LLP reported a revenue of ₹5.36 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹4.26 Lakh (net margin 0.8%) and EBITDA of ₹9.7 Lakh (EBITDA margin 1.8%). Revenue has grown at a compounded annual rate (CAGR) of 100% over three years and 107% over five years.

As per MCA filings, the LLP has open charges of ₹1 Cr on record.

Company details

LLPIN AAM-7893
Incorporation Date 08 June 2018
Total Obligation of Contribution ₹25 Lakh
ROC Ahmedabad
Company Status Active

Contact details

Curigen Pharmaceuticals LLP's registered office is in Surat, Gujarat.

  • Registered Address
    Office No. 105 First Floor Raghuveer Platinum, Kumbhariya, Surat, Gujarat, India – 395010
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Curigen Pharmaceuticals LLP - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Financials of Curigen Pharmaceuticals LLP

FY 2025 filings available

Curigen Pharmaceuticals LLP reported revenue of ₹5.36 Cr (up 515% YoY) for FY 2025.

Revenue · FY 2025
₹5.36 Cr ▲ 515%
Net profit · FY 2025
₹4.26 Lakh margin 0.8%
EBITDA · FY 2025
₹9.7 Lakh margin 1.8%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 515%
3 years · compounded
▲ 100%
5 years · compounded
▲ 107%
EBITDA CAGR growth
1 year
▲ 727%
3 years · compounded
▲ 178%
5 years · compounded
▲ 44%

Revenue has grown at a compounded annual rate (CAGR) of 107% over five years, including 515% growth in the latest year. EBITDA rose 727% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

Statement of Account and SolvencyFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income and Expenditure
Turnover
Other Income
Total Income
Purchases and Direct Costs
Personnel Expenses
Administrative Expenses
Interest
Depreciation
Total Expenses
Profit Before Tax
Tax
Profit After Tax₹4.26 Lakh
Profit Transferred to Partners
Assets and Liabilities
Partners' Contribution
Reserves and Surplus
Secured Loans
Unsecured Loans
Trade Payables
Other Liabilities and Provisions
Total Liabilities
Fixed Assets
Investments
Loans and Advances
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

Statement of Account and SolvencyFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
Net Profit Margin0.8%
Return on Partners' Funds
Return on Assets
Liquidity and Debt
Current Ratio
Debt to Partners' Funds
Interest Coverage
Efficiency and Growth
Asset Turnover
Receivable Days
Turnover Growth
Profit Growth

To see the full financial statements and ratios of Curigen Pharmaceuticals LLP, buy the company report.

Designated partners of Curigen Pharmaceuticals LLP

Curigen Pharmaceuticals has 3 current designated partners and 2 former designated partners. Current designated partners are listed first, with their designation and appointment date.

Current Designated Partners
NameDesignationAppointment DateTenureStatus
Krishna Sanjaykumar ManiyaDesignated Partner08 Jun 20188 Years 5 MonthsCurrent
Sanjaykumar Popatbhai ManiyaDesignated Partner19 Jul 20251 Years 3 MonthsCurrent
Nilesh Popatbhai ManiyaDesignated Partner09 Oct 20233 Years 1 MonthsCurrent

Peer comparison

Curigen Pharmaceuticals LLP is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Cardo Pharma Private Limited₹5.37 Cr (FY 2025)4.0%Patna, Bihar, India
Upsilon Pharmaceuticals Health Care Private Limited₹5.37 Cr (FY 2024)3.0%Gwalior, Madhya Pradesh, India
Jyoti Vishnu Pharma Private Limited₹5.37 Cr (FY 2025)3.0%Hyderabad, Telangana, India
JPM Pharma & Chemicals Private Limited₹5.36 Cr (FY 2024)80.0%Mumbai, Maharashtra, India
Aurocare Lifesciences Private Limited₹5.36 Cr (FY 2024)32.0%Ahmedabad, Gujarat, India
Curigen Pharmaceuticals LLPthis company₹5.36 Cr (FY 2025)₹4.26 Lakh0.8%515.0%Surat, Gujarat, India
Siddhakala Print Media and Publications Private Limited₹5.36 Cr (FY 2025)-3.0%Navi Mumbai, Maharashtra, India
Krishgir Pharmaceuticals Private Limited₹5.35 Cr (FY 2025)-18.0%Chandigarh, India
Brochem Healthcare Private Limited₹5.34 Cr (FY 2023)19.0%Navi Mumbai, Maharashtra, India
Sahyog Creations Private Limited₹5.34 Cr (FY 2024)Solapur, Maharashtra, India
Procyon Pharmaceuticals Private Limited₹5.34 Cr (FY 2025)19.0%Madurai, Tamil Nadu, India

To see the full peer comparison of Curigen Pharmaceuticals LLP, buy the company report.

Charges & borrowings

Open charges
₹1 Cr
Satisfied charges
None
Breakdown by lending institutions
Bank of India₹1.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
25 Jun 2024100961464Bank of India₹1 CrOpen

Total charge records: 1 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Curigen Pharmaceuticals LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Curigen Pharmaceuticals has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
24ADRFS5465M1Z9GujaratActive12 Oct 2018

To see the full GST registrations and return filing status of Curigen Pharmaceuticals LLP, buy the company report.

Recent activity

Curigen Pharmaceuticals LLP has 6 designated partner changes on record since 2018: 4 appointments and 2 cessations. The latest: Sanjaykumar Popatbhai Maniya was appointed as Designated Partner on 19 Jul 2025.

Appointed
Sanjaykumar Popatbhai Maniya was appointed as Designated Partner.
AGM
Curigen Pharmaceuticals Llp last Annual general meeting of members was held on 31 Mar 2025 as per latest MCA records.
Filing
Curigen Pharmaceuticals Llp has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Charges
A charge with Bank Of India amounted to Rs. 100.00 Lakh with Charge ID 100961464 was registered on 25 Jun 2024.
Appointed
Nilesh Popatbhai Maniya was appointed as Designated Partner.
Appointed
Janak Gopalbhai Lathia was appointed as Designated Partner.
Ceased
Jitendrabhai Dhirubhai Vaghasiya ceased to be Designated Partner.
Ceased
Janak Gopalbhai Lathia ceased to be Partner.
Appointed
Krishna Sanjaykumar Maniya was appointed as Designated Partner.
Incorporation
08 Jun 2018
Curigen Pharmaceuticals Llp was registered on 08 Jun 2018 with Roc Ahmedabad & aged 8 years 5 months as per MCA records.

Frequently asked questions

Curigen Pharmaceuticals is an active limited liability partnership based in Surat, Gujarat, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 08 June 2018 (8+ years old) and is registered under LLPIN AAM-7893.

Curigen Pharmaceuticals has 3 current designated partners:

The latest financial statements of Curigen Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 31 March 2025. Year-wise statements from FY 2019 are in the company report.

The GSTIN of Curigen Pharmaceuticals is 24ADRFS5465M1Z9, registered in Gujarat.

The LLPIN (Limited Liability Partnership Identification Number) of Curigen Pharmaceuticals is AAM-7893. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.

Curigen Pharmaceuticals was incorporated on 08 June 2018, making it 8+ years old. It is registered with the Registrar of Companies, Ahmedabad.

The peers of Curigen Pharmaceuticals by revenue are Cardo Pharma Private Limited, Upsilon Pharmaceuticals Health Care Private Limited, Jyoti Vishnu Pharma Private Limited, JPM Pharma & Chemicals Private Limited, Aurocare Lifesciences Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).

Sanjaykumar Popatbhai Maniya was appointed as Designated Partner on 19 Jul 2025. Nilesh Popatbhai Maniya was appointed as Designated Partner on 09 Oct 2023. Janak Gopalbhai Lathia was appointed as Designated Partner on 08 Mar 2021. Curigen Pharmaceuticals has 6 designated partner changes on record in total.

The registered office of Curigen Pharmaceuticals is at Office No. 105 First Floor Raghuveer Platinum, Kumbhariya, Surat, Gujarat, India – 395010.

Curigen Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.

Curigen Pharmaceuticals has open charges of ₹1 Cr and no satisfied charges on record as per latest MCA filings.